Alexandria, Egypt – December 18, 2018

PHARCO Pharmaceuticals, Inc. has announced that on the 18th of December 2018 the World Health Organization (WHO) granted prequalification for SOFOSBUVIR 400 mg Tablets, manufactured at its European Egyptian Pharmaceutical Industries (EEPI). On 11th of May 2018 this same factory had also been accredited by the WHO as a manufacturing facility.

Sherine Helmy, Pharco’s CEO, said “Today’s WHO prequalification for our Sofosbuvir 400 mg tablets is an important step in ensuring that HCV patients in developing countries are cured from HCV. PHARCO Pharmaceuticals is a major player in making the Egyptian dream “Egypt free from HCV by 2020” and the African dream “Africa free from HCV in 2025” come true. Access to medicine was a great challenge; it was our duty to overcome this challenge through providing the world with an affordable and accessible high quality treatment option.”

Hepatitis C is a chronic and life-threatening disease, approximately 400,000 people die each year from HCV either directly or through its complications. Egypt is a high endemic country, with infection rate estimates of about 8%.
In 2015 a revolutionary treatment has become available providing 95% cure rate in 3 months, however, it cost thousands of dollars.
Due to the Egyptian government’s efforts, the treatment became available at a very affordable price. Massive awareness and screening campaigns were executed all over the country aiming at eliminating the virus.
Accordingly, 1.5 million Egyptian patients have been treated, covering all registered patients nation-wide. An estimate of 6 million patients are still remaining, unaware and undiagnosed.

Sofosbuvir 400 mg tablets is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitorSofosbuvir 400 mg tablets is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.

Pharco Pharmaceuticals, Inc. is the largest manufacturer of pharmaceuticals in Egypt, focused on research, formulation, manufacturing and commercialization of pharmaceutical products. Today Pharco employs over 8,000 employees, and has over 500M sales units—ranking as the leader in the Egyptian pharmaceutical market. Pharco also exports to 47 countries around the world. Pharco works towards one goal; to provide highly effective and safe pharmaceutical products to patients at an affordable price.
For more information, please visit:
Pharco website at www.pharco.org
WHO website at: https://extranet.who.int/prequal/medicine/4172